about
Focus on adoptive T cell transfer trials in melanomaT helper 17 cells promote cytotoxic T cell activation in tumor immunityAdoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlookCompartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune functionNatural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cellsChimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytesCD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.Telomerase and primary T cells: biology and immortalization for adoptive immunotherapy.Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor modelChemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancerGene expression analysis of ex vivo expanded and freshly isolated NK cells from cancer patients.Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha.Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment.Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application.Adoptive cell therapy with autologous tumor-infiltrating lymphocytes and high-dose interleukin-2 for metastatic melanoma: The surgeon's perspectiveEfficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity.Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scaleImmunotherapy for gastrointestinal malignancies.IL-15 signaling promotes adoptive effector T-cell survival and memory formation in irradiation-induced lymphopeniaIL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapyCancer treatment: the combination of vaccination with other therapies.Cell vehicle targeting strategies.Subtle affinity-enhancing mutations in a myelin oligodendrocyte glycoprotein-specific TCR alter specificity and generate new self-reactivity.Novel therapeutics for the treatment of metastatic melanoma.Enhancing biological therapy through conditional regulation of protein stability.Therapeutic cancer vaccines in combination with conventional therapy.The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens.Use of NK cell activity in cure by transplant.The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase.Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions.Potent immunotherapy against well-established thymoma using adoptively transferred transgene IL-6-engineered dendritic cell-stimulated CD8+ T-cells with prolonged survival and enhanced cytotoxicity.Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells.Clinical safety of induced CTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients.Spatiotemporal control over molecular delivery and cellular encapsulation from electropolymerized micro- and nanopatterned surfaces.Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-α in Chinese Resected Stage III Malignant Melanoma.A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapyEnhancement of the cytotoxic activity of cytokine-induced killer cells transfected with IL3PE38KDEL gene against acute myeloid leukemia cells.Th17 and Th17-stimulated CD8⁺ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity.
P2860
Q21328679-F49E837A-F1A3-44CF-ADE4-EB7BB9D71A03Q24646584-23ACCEC0-AA15-444C-8383-38018777AD20Q27004178-A1345017-00B8-48A5-B42D-9508672A2B28Q28383385-8882B643-6A3F-400C-8D53-CBC2D31F85ABQ33445569-13927535-D20B-4D9E-AE83-C75ED590F372Q33791998-4DAFAD68-41D9-4599-9771-34814742B698Q33867018-10400F19-8122-4770-B697-711EC92A60EFQ34084756-4F4B2BE2-44B8-4971-BC7B-2DD6F2E47F3BQ34170012-208D4A9B-2073-4930-B615-4B758E0669D1Q34427459-3F5A6491-2A5F-41D9-8A19-B8BA4E26178DQ34757261-5C24B99B-A7F6-4E8D-9D29-30767F815234Q34777479-60DB1159-451A-403C-A4B6-9714AAFE9FC6Q34985704-23E2EC67-F41E-46AB-95E8-3F7BB7B9025BQ35057739-9347C286-07F8-4F3E-AD4E-0DB869ECA96BQ35214729-620F8BCB-94E8-4B2F-80B7-534C5DF3454DQ35982211-A031CBDE-C4C9-4F5B-87D6-68397ED0F687Q36224873-430313A7-3767-4F70-912B-D290CB6E2883Q36311669-895D2223-CA73-493C-86D4-133CBE89A98BQ36475411-26D91116-E2C2-4D91-8B2E-8B99FD5905C3Q36602174-7FF1B0C3-F1A0-43E6-AD05-EB4AC539EAC3Q36875832-8F824C97-3B3A-46F3-8043-7F40D8849848Q37041732-3DAF2D8E-6DEA-4E20-B329-C8FB87E14BE5Q37089001-C2EE84FC-EECB-4A5E-A97A-B64B4CFCF550Q37120169-0CAC45BE-CA34-42E8-B9A8-9515FD5D591FQ37190431-9E23D82B-B220-401F-9B7C-67CCEEB2B6F9Q37486788-39F13965-8DC7-4A4F-A8C2-F77EAF626DF7Q37671855-C43CF5B3-DAD4-4236-909B-0E30066A202BQ37771267-CC0AFEEC-E461-49B2-BC00-159B492D0BA3Q37838167-831FB21A-4F8F-4C3F-9D59-86CC8E647A17Q37910960-77DEB77C-DD91-4F67-A304-5C667EC7A6D4Q37990434-50996EFF-98F3-4ED1-810A-98E9E38A6EE4Q38149916-BB0D12D4-A16D-4BC1-B497-2F517B70A892Q38849071-C4348DC5-F66F-42F6-9A65-FA41195CF79BQ39904721-EDABDED6-CCE8-4393-851D-1D99E4D6D39FQ40278871-3B5FC6E4-3369-4949-AAAF-2B6E2D8B0FFBQ40324336-081D836D-19D3-49FE-8A99-3F73B6F953DFQ41622513-CCB509A9-E2AF-4349-ADA1-7CB41F0FF79BQ41859070-E5F3D24C-3523-49A2-B140-98E8F3498D21Q42462202-5A99E695-04BC-4766-9BA0-4E1876C2A01FQ44938649-FA80A0C9-68A1-4988-B9E6-2CAC11A0DBD5
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Adoptive cell transfer therapy
@ast
Adoptive cell transfer therapy
@en
type
label
Adoptive cell transfer therapy
@ast
Adoptive cell transfer therapy
@en
prefLabel
Adoptive cell transfer therapy
@ast
Adoptive cell transfer therapy
@en
P2860
P1433
P1476
Adoptive cell transfer therapy
@en
P2093
Mark E Dudley
Steven A Rosenberg
P2860
P304
P356
10.1053/J.SEMINONCOL.2007.09.002
P577
2007-12-01T00:00:00Z